title: Bortezomib is effective in primary plasma cell leukemia.
authors.forename: Damian P J
authors.initials: DP
authors.lastname: Finnegan
authors.forename: Paul
authors.initials: P
authors.lastname: Kettle
authors.forename: Mary
authors.initials: M
authors.lastname: Drake
authors.forename: Christine
authors.initials: C
authors.lastname: Matthews
authors.forename: H Denis
authors.initials: HD
authors.lastname: Alexander
authors.forename: Rakesh
authors.initials: R
authors.lastname: Popat
authors.forename: Jamie D
authors.initials: JD
authors.lastname: Cavanagh
authors.forename: William
authors.initials: W
authors.lastname: Wachsman
authors.forename: T C M
authors.initials: TC
authors.lastname: Morris
mesh_terms: D001856:Bone Marrow Examination; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib